Key points are not available for this paper at this time.
In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Steven P. Marso
Gilbert H. Daniels
Kirstine Brown‐Frandsen
New England Journal of Medicine
University of Toronto
Massachusetts General Hospital
University of North Carolina at Chapel Hill
Building similarity graph...
Analyzing shared references across papers
Loading...
Marso et al. (Mon,) studied this question.
www.synapsesocial.com/papers/695fc5b472b3a9f3be654075 — DOI: https://doi.org/10.1056/nejmoa1603827
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: